As part of the rollout of his faux health care plan, Donald Trump boasted yesterday that he’ll soon send $200 drug-discount cards to 33 million Medicare beneficiaries. “Nobody has seen this before,” the president said. “These cards are incredible.”
He added that the initiative, at a cost of $6.6 billion, would be paid for in part by a most-favored-nation-pricing program in which the United States will pay for medications through Medicare at the same rates as other countries.
But that made far less sense than the president seemed to realize: the most-favored-nation-pricing program the president pointed to doesn’t yet exist, so its savings can’t pay for these medication coupons.
This morning, Team Trump tried to clarify matters. The Wall Street Journal reported that the White House is actually planning to borrow from a Medicare trust fund for its election-season scheme, but the details remain murky.
Little information has been provided about how the discount-card program would be funded. Mr. Trump didn’t provide specifics about how the program would be funded or the legal authority allowing the federal government to send out the cards to seniors, prompting questions from health-policy experts. A spokesman at the Centers for Medicare and Medicaid Services, which oversees Medicare, on Thursday referred questions to the White House…. The White House declined to comment.
The article quoted David Mitchell, the founder of Patients For Affordable Drugs Now, a bipartisan Washington-based nonprofit that aims to lower drug prices, saying, “It is not at all clear if this is legal or how the president will pay for his scheme.”
Sure, but other than that, it’s fine.









